搜索到 1000 条关于 ㅵ 온라인홀덤게임 ㅃ rzc216.top ㈅ 드림게임 ㈇ 오빠게임 ㈚ 맞고홈페이지 ㅧ 대끼리 ㆊ 결투섯다주소 ㄻ 오매가바두기 ㄾ 배터리바둑이게임 的文章

七夕节:话一话古代十大奇葩避孕方式

2016.08.09 七夕节:话一话古代十大奇葩避孕方式

CRACKED 网站为大家来盘点了历史上奇葩十大避孕措施,看完之后你会觉得没有什么不可能,妇产君反正已经看到下颌脱臼了。Top 10 黄鼠狼睾丸欧洲正处于「黑暗时代」时期...吧。Top 9 鳄鱼便便创造出了金字塔、木乃伊的古埃及人,在避孕这件事上可以说是煞费苦心,想法也算得上简单粗暴。想要避免怀孕?只要用一些东西堵住不让精子进入

2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)

时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

5 Reasons To Attend
  • Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
  • Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
  • The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
  • Showcasing unique case studies from leading Asian and international biosimilar companies
  • Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success

Industry Gurus / Speakers
Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals

Past Attendees Include
Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)

Registration

FEES per delegate
Early Bird Rate
Register & Pay before 11 March 2011
Special Rate
Register & Pay before 15 April 2011
Normal Rate
Register & Pay after 15 April 2011
Group Rate
Group of 3 or more
?
US$ / CNY
US$ / CNY
US$ / CNY
US$ / CNY
4 day package
(Conf + Pre & Post Workshops)
2,495 /
16,600
2,695 /
17,950
2,895 /
19,500
2,175 /
14,650
3.5 day package (Conf + Workshop C & A or B )

2,295 /
15,500

2,495 /
16,600
2,695 /
17,950
2,025 /
13,500
3 day package (Conf + Workshop A & B or C)
1,995 /
13,500
2,195 /
14,600
2,395 /
15,950

1,795 /
12,000

2.5 day package (Conf + Workshop A or B)
1,795 /
12,000
1,995 /
13,500
2,195 /
14,600
1,695 /
10,950
2 day package
(Conf only)
1,495 /
9,950
1,695 /
11,300
1,895 /
12,600
1,495 /
9,950

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

  • Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
  • Payment by telegraphic transfer in S$ must be made to:
    IBC Asia (S) Pte Ltd
    A/C No.: 147-059513-001 (SGD)
    The Hongkong and Shanghai Banking Corporation Limited
    21 Collyer Quay, HSBC Building, Singapore 049320
    Bank Swift Code: HSBCSGSG
    Bank Code: 7232
  • Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
Payments by RMB (CNY)
  • Payment by telegraphic transfer in CNY must be made to:
    A/C Name:
    A/C No.: 720-031103-001
    Beneficiary Bank:
    Bank Address: No. 1000 Lujiazui Rind Road,
    Pudong, Shanghai 200120, P.R. China
    Bank Swift Code: HSBCCNSH
CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.
联系方式电话:+65 650 82401

2012.09.19 2010 第五届国际基因组学大会(ICG-V)

, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster

2012.09.19 2012 中国医疗器械高峰论坛

trials and regulatory affairs
A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China

2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)

。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱
老年肺癌患者:同步放化疗耐受性较差

2016.12.07 老年肺癌患者:同步放化疗耐受性较差

2009 年~2013 年确诊为 Ⅲ 期NSCLC 患者(N = 216),包括不可切除 Ⅲ 期 NSCLC,年龄为 70 岁。从荷兰肿瘤登记的医学数据中挖掘患者的治疗目的、耐受性(无计划入院,完成治疗)及生存期数据。总共有 216 例不可切除 Ⅲ 期 NSCLC 患者,接受同步放化疗(cCHRT
韩 MERS 病例持续增加医院道歉 欧洲首现疑似病例

2015.06.15 韩 MERS 病例持续增加医院道歉 欧洲首现疑似病例

」同处一个病房,当局却没有把他列为隔离观察对象,凸显医院和卫生当局的防控有多疏忽。在这之前,13 日被确诊感染 MERS 的三星医院急诊室护送人员曾与 216... 名患者,曾和 216 名医疗人员和患者密切接触。另一方面,在韩国肆虐的 MERS 疫情可能向外蔓延,在斯洛伐克首都布拉迪斯拉发,当地医院 13 日收治了一名

2011.12.09 经导管主动脉瓣置入术中CT的使用

Tel: 216-445-7579. E-mail: schoenp1@ccf.org.摘要:如果不及时治疗,有症状的严重主动脉狭窄(AS)的预后很差... Ave, Desk J 1-4, Cleveland, OH 44195. Tel: 216-445-7579. E-mail
基因芯片可有效预测 II 期结肠癌患者预后

2016.10.14 基因芯片可有效预测 II 期结肠癌患者预后

,CoIDx 认定 55% 的患者(216 例)为高风险,年龄、种族和错配修复(MMR)较多的男性、非白人和 MMR 完整的肿瘤与 CoIDx 显著相关。而 T
FDA 咨询委员会推荐批准山德士旗下依那西普生物仿制药

2016.07.18 FDA 咨询委员会推荐批准山德士旗下依那西普生物仿制药

,包括对生物仿制药的分析,临床前和临床研究,并对比了生物仿制药与参照产品。临床研究包括由 216 名健康志愿者参与的 4 项比较药代动力学(PK)研究
SODIUM-HF研究:限钠饮食可改善心衰患者生活质量

2014.12.08 SODIUM-HF研究:限钠饮食可改善心衰患者生活质量

从2137 mg/日降低至1398 mg/日,中钠饮食组钠摄入中位值从2678 mg/日降低至1461 mg/日。低钠饮食组中位BNP水平降低(216
天怒:超强台风卷走海南卫生系统近2亿元

2014.07.23 天怒:超强台风卷走海南卫生系统近2亿元

海南最强台风。台风造成全省216个乡镇受灾。受灾就诊人数4410人,重伤73人,轻伤952人。据海南省三防总指挥部提供的数据,截止20日,全省死亡人数11人(注
脑出血患者迟发性脑室内出血预后不良

2013.04.02 脑出血患者迟发性脑室内出血预后不良

是否为除已知预测因素外功能结局的独立预测因子,包括脑出血的评分的出血血肿的扩展情况。研究共纳入216例患者,其中104例(48%)初始时既有脑室
2012年中国学者SCI发文最偏好期刊

2013.02.03 2012年中国学者SCI发文最偏好期刊

2012年SCI收录至少有一位中国学者(不包括台湾地区)发表的论文183,216篇(截至到2013年2月1日按出版年统计),其中学术论文170,857篇、综述4,491篇、会议摘要4,253篇、会议论文1,629篇、社论1,541篇、通讯1,409篇、更正523篇、新闻115篇、丛书58篇、传记22篇、书评4篇
合并肺损害的原发性干燥综合征患者死亡率更高

2013.01.30 合并肺损害的原发性干燥综合征患者死亡率更高

(PFTs)出现特征性的异常改变。主区奥斯陆入组的患者中(117例),26例患者(22%)有肺损害;总队列(216例)中,59例患者(27%)出现肺

2012.09.19 2013中国(上海)医疗美容及整形设备展览会

面积从2011年的5700平方米增加到2012年的7600平方米;参展商数量由2011年的216家跃升到2012年的373家,创下了历史最好记录;观众
卒中后抗血小板出血风险有多大?有这10个特征需谨慎

2017.08.13 卒中后抗血小板出血风险有多大?有这10个特征需谨慎

)(即 S2TOP-BLEED 评分模型,见表1)。表 1 预测严重出血的S2TOP-BLEED 评分(来自多变量 Cox 回归模型)具体评分方法为,根据患者临床特征评估 S2TOP-BLEED 评分列表中每一栏分值,除了年龄相关的项目外,将其他所有项目分值想加得总分,再将总分代入图 1 所示风险分布图中,得到不同
远程协作治疗创伤后应激障碍

2014.12.23 远程协作治疗创伤后应激障碍

明,使用远程医疗工具,如电话,互动视频和共享电子病历进行的多学科PTSD非现场干预,即创伤后应激障碍远程医疗服务(TOP)与常规护理(UC)相比,治疗效果显著提升...包括了2009年11月至2011年9月份在CBOCs接受治疗的265名主要生活在农村的退伍军人。所有患者均符合PTSD诊断标准,他们被随机分配接受TOP治疗(N
上一页 1 2 3 ... 24 25 26 ... 48 49 50 下一页 到第